Pharmacological or genetic inhibition of REV-ERBα potently blocks the growth of drug-resistant tumors and effectively suppresses tumor LP, thus nominating REV-ERBα as an attractive target for treatment of advanced diseases with LP. This evidence concerns the gene NR1D1 and neoplasm.